Week 4 - Chronic Heart Failure Treatments Flashcards
What is the aim of treatment?
- improve status and functional capacity of patient,
- QoL,
- prevent hospital admission
- reduce mortality
What are the neuro-hormonal antagonists we use?
ACE inhibitors, ARB’s, ARNI
b blockers
MRA - mineralcorticoid receptor antagonist
What is a loop diuretic example and its role?
furosemide. inhibits ion transporters at loop of henle to reduce salt and water retention. works at low GFR’s
What are issues with loop diuretics?
- patient may become resistant by other transport mechanisms being activated
- oedema in gut may prevent drug absorption
- oedema may continue
How do you overcome loop diuretic resistance? Whats an issue?
furosemide with thiazides.
pee a lot. risk dehydration, hypotension, hyponatraemia, hypokalaemia
What ACE inhibitors are used?
ramipril, enalapril, lisinopril
What is the benefit and negatives of ACE inhibitors in HF patients?
- used first line. reduces mortality
- many ADR’s and drug-drug interractions
What is ARB’s and when is it used?
candesartan. angiotensin II receptor blockers. in ACE resistance or cough as a side effect.
What is an ARNI?
Valsartan-sacubitral
angiotensin II receptor blocker and neprilysin inhibitor combined. prevents breakdown of ANP and BNP.
When would ARNI be used?
- NYHA class II-IV symptoms
- In patients with EF 35% or less.
- those already taking ACE/ARB
What is the action of sacubitral?
inhibits neprilysin. that prevents the breakdown of ANP and BNP.
What 4 benefits do ANP and BNP provide in heart failure?
vasodilation, diuretics, natriuretics, and inhibit RAAS
What is a large benefit and a negative in ARNI?
significantly decrease hospitalisation and mortality rates more than ACE and ARB
in high doses may cause hypotension
What is a MRA?
mineralcorticosteroid receptor antagonist. diuretic.
block receptors that bind aldosterone, therefore causing Na+ loss and sparing K+, in distal tubule.
When is MRA used and what is its benefit?
in patients with symptoms despite other treatment - ACE/ARB/ARNI and B blockers
reduced hospitalisation and mortality significantly